According to the latest report by IMARC Group, titled “Plasma Fractionation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global plasma fractionation market size reached US$ 23.8 Billion in 2022. Plasma fractionation is a sophisticated biomedical process for producing various therapeutic products derived from human blood plasma. The technique involves the separation of blood plasma into its constituent components, such as proteins, clotting factors, and immunoglobulins, through a series of fractionation steps. This intricate process transforms plasma into valuable medical products, including albumin, immunoglobulins, clotting factors, and other specialized proteins. These plasma-derived therapies are pivotal in treating various medical conditions, ranging from immune deficiencies and hemophilia to neurological disorders. The therapeutic significance of plasma fractionation lies in harnessing the potency of specific proteins within plasma to develop life-saving medications. Despite its complexity, technological advancements in plasma fractionation have improved efficiency, yield, and safety, producing high-quality, purified products. Plasma fractionation also plays a crucial role in addressing global health challenges by providing therapies for rare diseases and contributing to emergency preparedness, particularly during health crises.
Global Plasma Fractionation Market Trends:
The global market is majorly driven by the growing prevalence of diseases such as immune deficiencies, hemophilia, and autoimmune disorders. In line with this, the increasing demand for plasma-derived therapies is significantly contributing to the market growth. Furthermore, the rising global geriatric population, prone to age-related conditions, contributes significantly to the expanding demand for these therapies. Moreover, technological advancements in plasma fractionation processes enhance production efficiency, ensuring a reliable and high-quality supply of plasma-derived products. Besides, the growing awareness about the importance of plasma donation, coupled with improved screening processes, is increasing the availability of source material for fractionation. The expanding applications of plasma-derived products, extending beyond traditional uses to include treatments for neurological disorders and certain cancers, further stimulate market growth. Additionally, the COVID-19 pandemic has accentuated the importance of plasma-derived therapies, such as convalescent plasma, in addressing emerging health challenges. The strategic role of plasma fractionation in emergency preparedness and its contribution to healthcare solutions for rare diseases also contribute to the market's sustained expansion. Looking forward, the market value is projected to reach US$ 33.7 Billion by 2028, expanding at a CAGR of 5.8% during 2023-2028.
- Based on the product, the market has been segmented as Immunoglobulins, Albumin, Coagulation factor VIII, and Coagulation factor IX.
- On the basis of the sector, the market has been divided as private and public sector.
- Based on the application, the market has been categorized into neurology, immunology, hematology, and other applications.
- Based on the end user, the market has been divided into hospitals and clinics, clinical research laboratories, and academic institutes.
- Region-wise, the market has been segmented into North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
- The competitive landscape of the market has also been examined, with some of the key players being ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd., and Virchow Biotech Private Limited.
|Base Year of the Analysis
| Historical Period
||Product, Sector, Application, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd. and Virchow Biotech Private Limited
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800